GlassScriptPhysician profile
Timothy C Dickey
NPI 1750621579
$15,736.44
in general payments reported to CMS, 2019-2025
34 companies · $3,918 in 2025
The $3,918 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,321 · 2022: $3,013 · 2023: $2,994 · 2024: $3,490 · 2025: $3,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $14.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,387.63 |
| Education | $14.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,002.40 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,482.58 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,205.47 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $907.19 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $855.20 | 2021-2025 | |
| Madrigal Pharmaceuticals | $553.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $545.93 | 2021-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $471.20 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $435.60 | 2021-2025 | Rebyota |
| Ardelyx, INC. | $391.15 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $363.59 | 2021-2024 | Dificid, Zinplava |
| Pfizer INC. | $331.16 | 2021-2025 | |
| Genzyme Corporation | $277.76 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $252.91 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $249.36 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $188.79 | 2023-2025 | Omvoh |
| Celgene Corporation | $184.31 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $182.02 | 2023-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $176.93 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $159.15 | 2022-2025 | Linzess |
| Hologic Sales and Service, LLC | $81.60 | 2024-2025 | Aptima |
| Qol Medical, LLC | $81.23 | 2024-2025 | Sucraid, Sucraid |
| Evoke Pharma, INC. | $80.32 | 2022-2024 | Gimoti |
| Daiichi Sankyo INC. | $64.84 | 2022-2024 | Injectafer |
| Redhill Biopharma INC. | $40.46 | 2022 | |
| Mauna Kea Technologies, INC. | $24.54 | 2025 | |
| Sandoz INC. | $23.72 | 2024 | Hyrimoz |
| Novo Nordisk INC | $23.12 | 2025 | Wegovy |
| Exact Sciences Corporation | $22.26 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $18.60 | 2024 | Gi Genius |
| Shield Therapeutics INC | $16.41 | 2025 | |
| Emd Serono, INC. | $16.23 | 2021 | |
| Celltrion USA INC. | $14.65 | 2024 | Zymfentra |
| Alfasigma USA, INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Dickey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.